title: Novel agents in development for peripheral T-cell lymphoma.
abstract: Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are noticeably absent. Combinations of T-cell centric agents could produce novel platforms of therapy to replace the relatively ineffective CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimens. Among agents with T-cell activity are the folate analog pralatrexate, histone deacetylase inhibitors (HDACi) like romidepsin, the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the purine nucleoside phosphorylase (PNP) inhibitor forodesine, the nucleoside analog gemcitabine, and BH3-only mimetics like ABT-263 and ABT-737.
authors.affiliation: New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA. O'Connor@nyumc.org
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
mesh_terms: D000630:Aminopterin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D047630:Depsipeptides / Q000627:therapeutic use; D015195:Drug Design; D015507:Drugs, Investigational / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077269:Lenalidomide; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D011684:Purine Nucleosides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D016879:Salvage Therapy; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: C418863:10-propargyl-10-deazaaminopterin; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001897:Boronic Acids; D047630:Depsipeptides; D015507:Drugs, Investigational; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D011684:Purine Nucleosides; D011719:Pyrazines; D011744:Pyrimidinones; C113101:forodesine; D013792:Thalidomide; D000069286:Bortezomib; C087123:romidepsin; D000077269:Lenalidomide; D000630:Aminopterin